Hc Advisors, LLC Alx Oncology Holdings Inc Transaction History

Hc Advisors, LLC

$126 Million
Q1 2025

A detailed history of Hc Advisors, LLC transactions in Alx Oncology Holdings Inc stock. As of the latest transaction made, Hc Advisors, LLC holds 21,500 shares of ALXO stock, worth $11,610. This represents 0.01% of its overall portfolio holdings.

Number of Shares

21,500

Previous 15,475 38.93%

Holding current value

$11,610

Previous $25,000 48.0%

% of portfolio

0.01%

Previous 0.02%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 13, 2025	BUY	$0.62 - $1.86 $3,735 - $11,206	6,025 Added 38.93%	21,500 $13,000
Q4 2024 Feb 05, 2025	SELL	$1.21 - $1.87 $363 - $561	-300 Reduced 1.9%	15,475 $25,000
Q3 2024 Nov 05, 2024	BUY	$1.81 - $8.13 $28,552 - $128,250	15,775 New	15,775 $28,000
Q3 2022 Nov 10, 2022	SELL	$8.23 - $15.14 $1,563 - $2,876	-190 Reduced 1.35%	13,933 $133,000
Q2 2022 Aug 08, 2022	BUY	$5.89 - $19.46 $1,961 - $6,480	333 Added 2.41%	14,123 $114,000
Q1 2022 May 06, 2022	SELL	$13.65 - $22.06 $57,357 - $92,696	-4,202 Reduced 23.35%	13,790 $233,000
Q4 2021 Feb 02, 2022	BUY	$21.49 - $74.4 $210,301 - $728,078	9,786 Added 119.25%	17,992 $387,000
Q3 2021 Oct 29, 2021	SELL	$52.51 - $80.91 $30,035 - $46,280	-572 Reduced 6.52%	8,206 $606,000
Q2 2021 Aug 09, 2021	SELL	$52.2 - $75.23 $8,717 - $12,563	-167 Reduced 1.87%	8,778 $480,000
Q1 2021 May 07, 2021	SELL	$62.84 - $87.68 $53,916 - $75,229	-858 Reduced 8.75%	8,945 $660,000
Q4 2020 Feb 08, 2021	BUY	$34.11 - $112.26 $112,563 - $370,458	3,300 Added 50.75%	9,803 $845,000
Q3 2020 Nov 04, 2020	BUY	$29.36 - $47.1 $190,928 - $306,291	6,503 New	6,503 $245,000

Others Institutions Holding ALXO

# of Institutions

Shares Held

35.3M

Call Options Held

34K

Put Options Held

36.9K

View Full List

About ALX ONCOLOGY HOLDINGS INC

Ticker ALXO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 40,747,100
Market Cap $22M
Description
ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for patients fighting cancer. Its lead product candidate is ALX148, a CD47 blocking therapeutic that is in Phase 1b/2 clinical trial used for the treatment of myelodysplastic syndromes; and for the treatment of acute myeloid leukemia and non-Hod...

More about ALXO

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Hc Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Hc Advisors, LLC with notifications on news.

Account